PL2086940T3 - Sól fumaranowa (alfa S, beta R)-6-bromo-alfa-[2-(dimetyloamino)etylo]-2-metoksy-alfa-1-naftalenylo-beta-fenylo-3-chinolinoetanolu - Google Patents

Sól fumaranowa (alfa S, beta R)-6-bromo-alfa-[2-(dimetyloamino)etylo]-2-metoksy-alfa-1-naftalenylo-beta-fenylo-3-chinolinoetanolu

Info

Publication number
PL2086940T3
PL2086940T3 PL07847697T PL07847697T PL2086940T3 PL 2086940 T3 PL2086940 T3 PL 2086940T3 PL 07847697 T PL07847697 T PL 07847697T PL 07847697 T PL07847697 T PL 07847697T PL 2086940 T3 PL2086940 T3 PL 2086940T3
Authority
PL
Poland
Prior art keywords
alpha
beta
quinolineethanol
naphthalenyl
dimethylamino
Prior art date
Application number
PL07847697T
Other languages
English (en)
Polish (pl)
Inventor
Jean François Alexandre Lucas HEGYI
Wim Albert Alex Aelterman
Yolande Lydia Lang
Sigrid Carl Maria Stokbroekx
Carina Leys
Remoortere Peter Jozef Maria Van
Anne Faure
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2086940(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL2086940T3 publication Critical patent/PL2086940T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL07847697T 2006-12-05 2007-12-03 Sól fumaranowa (alfa S, beta R)-6-bromo-alfa-[2-(dimetyloamino)etylo]-2-metoksy-alfa-1-naftalenylo-beta-fenylo-3-chinolinoetanolu PL2086940T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
EP07847697A EP2086940B1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
PL2086940T3 true PL2086940T3 (pl) 2012-10-31

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07847697T PL2086940T3 (pl) 2006-12-05 2007-12-03 Sól fumaranowa (alfa S, beta R)-6-bromo-alfa-[2-(dimetyloamino)etylo]-2-metoksy-alfa-1-naftalenylo-beta-fenylo-3-chinolinoetanolu

Country Status (34)

Country Link
US (1) US8546428B2 (cg-RX-API-DMAC7.html)
EP (1) EP2086940B1 (cg-RX-API-DMAC7.html)
JP (2) JP2010511663A (cg-RX-API-DMAC7.html)
KR (1) KR101514700B1 (cg-RX-API-DMAC7.html)
CN (2) CN101547904A (cg-RX-API-DMAC7.html)
AP (1) AP2498A (cg-RX-API-DMAC7.html)
AR (1) AR064149A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007328945B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719693A2 (cg-RX-API-DMAC7.html)
CA (1) CA2668512C (cg-RX-API-DMAC7.html)
CL (1) CL2007003472A1 (cg-RX-API-DMAC7.html)
CY (1) CY1113594T1 (cg-RX-API-DMAC7.html)
DK (1) DK2086940T3 (cg-RX-API-DMAC7.html)
EA (1) EA017091B9 (cg-RX-API-DMAC7.html)
ES (1) ES2387923T3 (cg-RX-API-DMAC7.html)
HK (1) HK1214513A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20120639T1 (cg-RX-API-DMAC7.html)
IL (1) IL199077A (cg-RX-API-DMAC7.html)
JO (1) JO2973B1 (cg-RX-API-DMAC7.html)
ME (1) ME01456B (cg-RX-API-DMAC7.html)
MX (1) MX2009005909A (cg-RX-API-DMAC7.html)
MY (1) MY148844A (cg-RX-API-DMAC7.html)
NO (1) NO342773B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ576485A (cg-RX-API-DMAC7.html)
PE (1) PE20081350A1 (cg-RX-API-DMAC7.html)
PL (1) PL2086940T3 (cg-RX-API-DMAC7.html)
PT (1) PT2086940E (cg-RX-API-DMAC7.html)
RS (1) RS52408B (cg-RX-API-DMAC7.html)
SI (1) SI2086940T1 (cg-RX-API-DMAC7.html)
TW (1) TWI417098B (cg-RX-API-DMAC7.html)
UA (1) UA97813C2 (cg-RX-API-DMAC7.html)
UY (1) UY30762A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008068231A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200903907B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) * 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
CN114129526A (zh) * 2015-01-27 2022-03-04 詹森药业有限公司 可分散组合物
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) * 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
WO2017066926A1 (zh) * 2015-10-20 2017-04-27 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
PT3971177T (pt) * 2016-07-20 2024-07-30 Novartis Ag Derivados de aminopiridina e a sua utilização como inibidores seletivos de alk-2
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
PE20200336A1 (es) 2017-07-14 2020-02-14 Janssen Pharmaceutica Nv Formulaciones a largo plazo
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
CN113271930A (zh) 2019-01-09 2021-08-17 詹森药业有限公司 治疗非结核分枝杆菌疾病的组合
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
JP2023549605A (ja) 2020-11-12 2023-11-28 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性マイコバクテリア疾患の治療におけるベダキリン、エタンブトール、及びマクロライドの組合せ
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
CA2270123A1 (en) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
CZ300261B6 (cs) * 1996-10-30 2009-04-01 Eli Lilly And Company Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
EP2301544B1 (en) * 2002-07-25 2012-09-19 Janssen Pharmaceutica N.V. Quinoline derivatives as intermediates to mycobacterial inhibitors
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AU2005249231B2 (en) * 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
BG66437B1 (bg) * 2004-12-24 2014-07-31 Janssen Pharmaceutica N.V. Използване на хинолинови съединения за лечение на латентна туберкулоза

Also Published As

Publication number Publication date
TWI417098B (zh) 2013-12-01
JO2973B1 (en) 2016-03-15
PE20081350A1 (es) 2008-09-18
CA2668512A1 (en) 2008-06-12
MX2009005909A (es) 2009-06-16
HRP20120639T1 (hr) 2012-08-31
KR20090087020A (ko) 2009-08-14
CN101547904A (zh) 2009-09-30
HK1214513A1 (zh) 2016-07-29
ES2387923T3 (es) 2012-10-04
UA97813C2 (uk) 2012-03-26
CY1113594T1 (el) 2016-06-22
AU2007328945B2 (en) 2014-04-03
WO2008068231A1 (en) 2008-06-12
ZA200903907B (en) 2013-08-28
IL199077A (en) 2016-09-29
EP2086940B1 (en) 2012-05-16
AU2007328945A1 (en) 2008-06-12
RS52408B (sr) 2013-02-28
JP2010511663A (ja) 2010-04-15
JP5894239B2 (ja) 2016-03-23
AP2498A (en) 2012-10-19
DK2086940T3 (da) 2012-08-20
EA017091B9 (ru) 2014-10-30
TW200838527A (en) 2008-10-01
US20100028428A1 (en) 2010-02-04
JP2015028049A (ja) 2015-02-12
UY30762A1 (es) 2008-07-03
SI2086940T1 (sl) 2012-09-28
CN105012303A (zh) 2015-11-04
US8546428B2 (en) 2013-10-01
NO20092535L (no) 2009-08-06
PT2086940E (pt) 2012-08-09
EA017091B1 (ru) 2012-09-28
NO342773B1 (no) 2018-08-06
NZ576485A (en) 2012-01-12
CL2007003472A1 (es) 2008-08-22
ME01456B (me) 2014-04-20
EA200970532A1 (ru) 2009-10-30
AP2009004870A0 (en) 2009-06-30
BRPI0719693A2 (pt) 2013-12-24
CA2668512C (en) 2015-03-24
AR064149A1 (es) 2009-03-18
EP2086940A1 (en) 2009-08-12
MY148844A (en) 2013-06-14
KR101514700B1 (ko) 2015-04-24

Similar Documents

Publication Publication Date Title
AP2498A (en) Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
EP2046259A4 (en) PATIENTS LIEGE
GB0610680D0 (en) Therapeutic compounds
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
IL193678A0 (en) Therapeutic compounds
ZA200806568B (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
GB2458228B (en) External preparation for skin
ZA200900004B (en) Therapeutic compounds
GB0606663D0 (en) Therapeutic compounds
GB0615809D0 (en) Therapeutic compounds
GB0612971D0 (en) Therapeutic compounds
IL205752A0 (en) Octahydroquinolizines for antidiabetic treatment
GB0625349D0 (en) Therapeutic compounds
GB0625345D0 (en) Therapeutic compounds
GB0605573D0 (en) Therapeutic Compounds
ZA200903242B (en) Treatment for multiple myeloma
GB0608269D0 (en) Therapeutic compounds
ITMI20060760A1 (it) Procedimento per il trattamento di tessuti
GB0613584D0 (en) Therapeutic compounds
AU312984S (en) Headgear for patient interface
AU312983S (en) Headgear for patient interface
GB0604049D0 (en) Therapeutic compounds
GB0610670D0 (en) Therapeutic compounds
GB0614082D0 (en) Therapeutic compounds
GB0619687D0 (en) Therapeutic compounds